SCHEMBL4672489

SCHEMBL4672489

CC(=O)c1ccc(Cc2ccc(C(=O)/C=C(\O)C(=O)O)[nH]2)cc1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.46
LMNA P02545 1/20 0.45
HSD17B10 Q99714 1/20 0.36
PYCR1 P32322 1/20 0.34
TSHR P16473 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.32
TBXAS1 P24557 2/20 0.32
ALDH1A1 P00352 2/20 0.32
HTT P42858 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
MAOB P27338 6/20 0.32
MAPT P10636 2/20 0.32
MMP12 P39900 1/20 0.32
MMP13 P45452 1/20 0.32
KDM1A O60341 1/20 0.31
RCOR1 Q9UKL0 1/20 0.31
MAOA P21397 1/20 0.31
ITK Q08881 1/20 0.31
SRD5A2 P31213 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4672498 1.00 KMT2A (0.46) KMT2ALMNAHSD17B10PYCR1TSHR
SCHEMBL4676889 0.86 SRD5A2 (0.38) LMNAHSD17B10SMN1; SMN2ALDH1A1HTT
SCHEMBL4676895 0.86 SRD5A2 (0.38) LMNAHSD17B10SMN1; SMN2ALDH1A1HTT
SCHEMBL4680678 0.85 HCAR2 (0.38) LMNASMN1; SMN2ITK
SCHEMBL4680681 0.85 HCAR2 (0.38) LMNASMN1; SMN2ITK
SCHEMBL4676710 0.84 ITGB1 (0.38) TSHRALDH1A1
SCHEMBL4670505 0.84 DAO (0.36) KMT2ALMNAALDH1A1L3MBTL1MMP12
SCHEMBL4670507 0.84 DAO (0.36) KMT2ALMNAALDH1A1L3MBTL1MMP12
SCHEMBL4676715 0.84 ITGB1 (0.38) TSHRALDH1A1
SCHEMBL4677663 0.83 KDM5A (0.42) SMN1; SMN2ALDH1A1HTTMMP12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 KMT2A 597/4885LMNA 659/4885HSD17B10 241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.